Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801869 | 0.78 | CYP1A2 (0.55) | CYP1A2KMT2AMEN1 | |
| SCHEMBL441004 | 0.72 | — | — | |
| SCHEMBL20268120 | 0.70 | ALDH1A1 (0.43) | CYP1A2CA12CA1CA2CA9 | |
| SCHEMBL2852145 | 0.67 | NOTUM (0.32) | — | |
| SCHEMBL1040746 | 0.67 | NOTUM (0.32) | — | |
| SCHEMBL8887619 | 0.67 | BAZ2B (0.50) | CYP1A2KMT2ATDP1 | |
| SCHEMBL170375 | 0.66 | — | — | |
| SCHEMBL3861670 | 0.66 | — | — | |
| SCHEMBL1204641 | 0.66 | — | — | |
| SCHEMBL8808976 | 0.66 | LPO (0.38) | CYP1A2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0785937-A1 | 2-(IMIDAZOL-4-YL)CARBAPENEME DERIVATIVES, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011932-A1 | 2-(IMIDAZOL-4-YL)CARBAPENEME DERIVATIVES, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-25 | — | — | WO | disclosed |